Merrill Cuts Pharmaceutical Resources to 'Neutral'

Analyst Gregory Gilbert sees earnings and cash flow upside from the drugmaker's generic Paxil

Merrill Lynch downgraded Pharmaceutical Resources (PRX ) to neutral from buy.

Analyst Gregory Gilbert says ever since the drugmaker launched a generic version of antidepressant Paxil on Sept. 8, its stock is up about $11. While Gilbert thinks the upwards move may be justified, he also thinks the Street's estimates may be too low for 2003 and 2004 and he expects the stock to take a breather.

Gilbert has confidence that management will take advantage of this period of earnings and cash flow upside to improve the long-term growth potential -- maybe in the form of increased R&D spending and M&A activity. He sees $3.34 2003 earnings per share (GAAP), and $3.66 for 2004. Additionally, he notes Pharmaceutical Resources could deliver results well ahead of estimates if no other generic companies launch generic Paxil in the coming quarters.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE